Biotech entity

Dr. Jay Mei

Person

pharma is the sole category represented across all 1 tracked stories. Dr. Jay Mei is most often covered alongside ATG-201, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Dr. Jay Mei appears in 1 tracked Biotech story from March 4, 2026.

Last mentioned: Mar 4, 2026

RSS updates
Share

Entity pulse

Recent coverage · Dr. Jay Mei

1 story
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Dr. Jay Mei

pharma is the sole category represented across all 1 tracked stories. Dr. Jay Mei is most often covered alongside ATG-201, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Dr. Jay Mei appears in 1 tracked Biotech story from March 4, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Dr. Jay Mei. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Investor Briefings

    Antengene hosts dual-language conference calls to discuss the UCB partnership and pipeline impact.

  2. Global License Agreement

    Antengene and UCB announce the $1.1B+ licensing deal for ATG-201.

  3. Regulatory Filings

    Planned submission of clinical trial applications for ATG-201 in China and Australia.

Stories mentioning Dr. Jay Mei 1

Pharma Positive

UCB and Antengene Ink $1.1B Deal for CD19 Bispecific in Autoimmune Pivot

Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.

2 sources

Dr. Jay Mei is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.